IMT504, a non-CpG 24-mer oligodeoxynucleotide, is an immunomodulatory oligonucleotide currently being investigated as a rabies vaccine. IMT504 has been previously proven to be effective in animal models of vaccine potency, chronic lymphocytic leukemia, tissue regeneration, and sepsis.
Einzelnachweise
[1] Franco R, Rodriguez JM, Elías F, et al. Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide.?Nucleic Acid Ther. 2014;24(4):267-282. doi:10.1089/nat.2013.0479 DOI:10.1089/nat.2013.0479
